Chimeric Therapeutics Achieves 60% Complete Response in AML Trial
Chimeric Therapeutics' CHM CORE-NK cell therapy achieved a 60% complete response rate in high-risk frontline AML patients, significantly exceeding typical outcomes and maintaining a strong safety profile.
- 60% CR/CRi rate in 25 high-risk AML patients
- Combination therapy with azacitidine and venetoclax well tolerated
- Trial ongoing at MD Anderson Cancer Center
- Standard care response rates typically 20-30%
- Investigator-initiated Phase 1B clinical trial
Breakthrough Response Rates in High-Risk AML
Chimeric Therapeutics (ASX:CHM) has unveiled compelling interim results from its ADVENT-AML Phase 1B trial, reporting a 60% complete response or complete response with incomplete count recovery (CR/CRi) rate in 25 enrolled high-risk acute myeloid leukemia (AML) patients. This outcome markedly outperforms the typical 20-30% response rates observed with standard frontline therapies for this challenging patient group.
The trial combines the company’s off-the-shelf CHM CORE-NK cell therapy with the established drugs azacitidine and venetoclax. Importantly, the regimen continues to be well tolerated with no unexpected safety issues, reinforcing the potential for this combination to redefine frontline treatment options.
Investigator-Led Study at MD Anderson
Conducted at the University of Texas MD Anderson Cancer Center under the leadership of Dr Abhishek Maiti, the investigator-initiated trial is enrolling patients unsuitable for intensive chemotherapy or stem cell transplantation. This study represents the first clinical evaluation of NK cell therapy synergy with standard AML care in the frontline setting, a novel approach that could shift treatment paradigms.
The CHM CORE-NK cells are manufactured and cryopreserved for immediate use at Case Western Reserve University, where the technology was developed. Translational analyses including persistence and cytokine profiling are underway to deepen understanding of the therapy’s mechanism and durability.
Building on a Diversified Pipeline
Chimeric’s CEO, Dr Rebecca McQualter, emphasised the significance of these findings as a pioneering step in cell therapy for AML. The company’s broader portfolio includes the CHM CDH17 CAR T therapy, currently in Phase 1/2 trials targeting gastrointestinal and neuroendocrine tumours, highlighting its multi-pronged oncology strategy.
This announcement follows Chimeric’s recent $8.4M funding boost, which supports ongoing clinical programs including CORE-NK and CAR T developments. The infusion of capital and positive clinical momentum position Chimeric to advance its innovative therapies despite the inherent uncertainties of early-stage trials.
Next Steps and Questions Ahead
The ADVENT-AML trial remains open to enrolling up to three additional patients, with longer-term efficacy and safety data pending. As the company progresses, the durability of responses, potential for regulatory approvals, and competitive positioning against emerging AML treatments will be critical to watch.
Bottom Line?
While interim results are promising, the path from Phase 1B signals to clinical standard remains contingent on larger cohorts and sustained safety profiles.
Questions in the middle?
- Will the 60% response rate hold as more patients enroll and data matures?
- How durable are the remissions achieved with CHM CORE-NK combined with standard care?
- What regulatory pathways will investigator-initiated trials like ADVENT-AML follow for approval?
